GlassScriptPhysician profile
Michael P Subichin
NPI 1043500812
$1,311.68
in general payments reported to CMS, 2019-2025
12 companies · $623 in 2025
The $623 reported for 2025 was more than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $12.17 · 2022: $23.15 · 2023: $86.47 · 2024: $325 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,033.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $705.35 | 2024-2025 | |
| Allergan, INC. | $277.70 | 2019-2022 | |
| Aroa Biosurgery Incorporated | $56.82 | 2024-2025 | |
| Integra Lifesciences Corporation | $54.13 | 2024-2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Medtronic, INC. | $42.88 | 2024 | Signia |
| W. L. Gore & Associates, INC. | $40.02 | 2024 | Gore Enform Preperitoneal Biomaterial |
| Polynovo North America LLC | $38.94 | 2023 | |
| Stryker Corporation | $27.33 | 2023 | Na, Smartlock, Stryker Varispeed |
| Tela Bio, INC. | $20.80 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Checkpoint Surgical, INC | $20.20 | 2023 | Checkpoint Stimulators |
| Kerecis Limited | $14.09 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Avita Medical Americas, LLC | $13.42 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Subichin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.